Apogee Therapeutics inc   (APGE)
Other Ticker:  
Price: $47.8600 $-0.17 -0.354%
Day's High: $49.389 Week Perf: -2.74 %
Day's Low: $ 46.71 30 Day Perf: 1.55 %
Volume (M): 334 52 Wk High: $ 72.29
Volume (M$): $ 15,971 52 Wk Avg: $34.70
Open: $48.19 52 Wk Low: $14.19

 Market Capitalization (Millions $) 2,402
 Shares Outstanding (Millions) 50
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -72
 Cash Flow (TTM) (Millions $) 404
 Capital Exp. (TTM) (Millions $) 0

Apogee Therapeutics Inc
Apogee Therapeutics Inc. is a biotechnology company focused on the development of novel therapeutics for the treatment of various diseases. The company specializes in the discovery and development of small molecule drugs targeting specific biological pathways involved in disease processes. Apogee's goal is to create innovative and effective treatments that address unmet medical needs and improve patient outcomes. The company employs advanced technologies and collaborations with academic and industry partners to accelerate the development of their therapeutic candidates. Overall, Apogee Therapeutics aims to make a significant impact on the field of medicine by bringing new and improved treatments to patients worldwide.

   Company Address: 221 Crescent St. Waltham 2453 MA
   Company Phone Number: 394-5230   Stock Exchange / Ticker: NASDAQ APGE
   APGE is expected to report next financial results on August 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Published Wed, May 15 2024 8:01 PM UTC

'Apogee Therapeutics Initiates Phase 2 Clinical Trial of APG777 for Atopic Dermatitis Following Promising Phase 1 Results''' Apogee Therapeutics recently announced the commencement of dosing in their Phase 2 clinical trial for APG777, a novel subcutaneous, half-life extended anti-IL-13 antibody. This drug is being investigated for the treatment of atopic dermatitis and oth...

Clinical Study

Apogee Therapeutics Breaks Ground with Promising Drug Pipeline and Strong Q1 2024 Performance: Eagerly Awaits Game-Changing Data for Atopic Dermatitis Treatment

Published Mon, May 13 2024 11:00 AM UTC

Apogee Therapeutics Advances Promising Drug Pipeline and Acknowledges Strong First Quarter 2024 Financial Performance: Anticipates Key Data Release for APG777 in Late 2025Apogee Therapeutics, a leading biopharmaceutical company, is making remarkable progress in its pursuit of innovative therapies for patients suffering from debilitating conditions. The company recently annou...

Clinical Study

APG808: A Promising Half-life Extended IL-4R Antibody for Improved Treatment of Inflammatory Diseases

Published Mon, Mar 25 2024 11:00 AM UTC

Apogee Therapeutics, a biopharmaceutical company, has announced the dosing of the first participants in a Phase 1 trial for APG808, a novel half-life extended IL-4R antibody. This antibody is being investigated for its potential in treating Chronic Obstructive Pulmonary Disease (COPD) and other inflammatory diseases.The preclinical data with APG808 has shown promising result...


Apogee Therapeutics, Inc. Successfully Closes Upsized Public Offering, Securing $483 Million for Groundbreaking Biologics Development

Published Tue, Mar 12 2024 8:01 PM UTC

Apogee Therapeutics, Inc., a clinical-stage biotechnology company focused on developing cutting-edge biologics for various inflammatory and immunology indications, proudly announced the completion of an upsized public offering and the full exercise of the underwriters option to purchase additional shares. The company raised a remarkable $483 million in gross proceeds, p...


Apogee Therapeutics Raises $420 Million in Upsized Public Offering, Accelerating Biologics Development for Inflammatory and Immunology Diseases

Published Thu, Mar 7 2024 11:50 PM UTC

Apogee Therapeutics Announces Upsized Public Offering, Raising $420 Million for Biologics Development
San Francisco and Waltham, Mass., March 07, 2024 - Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company focused on developing differentiated biologics for various inflammatory and immunology indications, has recently announced the pricing of i...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com